Common Stock, $0.0001 par value per share
- Symbol
- IXHL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Annual Report · 10-K
IXHLNASDAQEQUITYCurrent
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies and next-generation medicines for conditions with significant unmet medical need. The Company’s lead programs include IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder. Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and creating long-term shareholder value. For more information, please visit www.incannex.com.
Incannex Healthcare Inc. · 10-K · Filed 2026-09-25